<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article
  PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">JRA</journal-id>
<journal-id journal-id-type="hwp">spjra</journal-id>
<journal-id journal-id-type="nlm-ta">J Renin Angiotensin Aldosterone Syst</journal-id>
<journal-title>Journal of the Renin-Angiotensin-Aldosterone System</journal-title>
<issn pub-type="ppub">1470-3203</issn>
<issn pub-type="epub">1752-8976</issn>
<publisher>
<publisher-name>SAGE Publications</publisher-name>
<publisher-loc>Sage UK: London, England</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.1177/1470320311423281</article-id>
<article-id pub-id-type="publisher-id">10.1177_1470320311423281</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Articles</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Haemodynamic effects of aliskiren in decompensated severe heart failure</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author" corresp="yes">
<name><surname>Brancalhao</surname><given-names>Euler O</given-names></name>
</contrib>
<contrib contrib-type="author">
<name><surname>Ochiai</surname><given-names>Marcelo E</given-names></name>
</contrib>
<contrib contrib-type="author">
<name><surname>Cardoso</surname><given-names>Juliano N</given-names></name>
</contrib>
<contrib contrib-type="author">
<name><surname>Vieira</surname><given-names>Kelly R</given-names></name>
</contrib>
<contrib contrib-type="author">
<name><surname>Puig</surname><given-names>Raphael N</given-names></name>
</contrib>
<contrib contrib-type="author">
<name><surname>Lima</surname><given-names>Marcelo V</given-names></name>
</contrib>
<contrib contrib-type="author">
<name><surname>Barretto</surname><given-names>Antonio P</given-names></name>
</contrib>
<aff id="aff1-1470320311423281">University of Sao Paulo, Cotoxo Hospital, Heart Institute (InCor), Sao Paulo, Brazil</aff>
</contrib-group>
<author-notes>
<corresp id="corresp1-1470320311423281">Euler Ochiai Brancalhao, University of Sao Paulo, Rua Cotoxo 1142, Sao Paulo, 05021010, Brazil. Email: <email>eulerbrancalhao@gmail.com</email></corresp>
</author-notes>
<pub-date pub-type="epub-ppub">
<month>3</month>
<year>2012</year>
</pub-date>
<volume>13</volume>
<issue>1</issue>
<fpage>128</fpage>
<lpage>132</lpage>
<permissions>
<copyright-statement>© SAGE Publications 2011</copyright-statement>
<copyright-year>2011</copyright-year>
<copyright-holder content-type="sage">SAGE Publications</copyright-holder>
</permissions>
<abstract>
<p><italic>Aim</italic>: The renin–angiotensin–aldosterone system (RAAS) has dual pathways to angiotensin II production; therefore, multiple blockages may be useful in heart failure. In this study, we evaluated the short-term haemodynamic effects of aliskiren, a direct renin inhibitor, in patients with decompensated severe heart failure who were also taking angiotensin-converting enzyme (ACE) inhibitors.</p>
<p><italic>Materials and methods</italic>: A total of 16 patients (14 men, two women, mean age: 60.3 years) were enrolled in the study. The inclusion criteria included hospitalisation due to decompensated heart failure, ACE inhibitor use, and an ejection fraction &lt; 40% (mean: 21.9 ± 6.7%). The exclusion criteria were: creatinine &gt; 2.0 mg/dl, cardiac pacemaker, serum K<sup>+</sup> &gt; 5.5 mEq/l, and systolic blood pressure &lt; 70 mmHg. Patients either received 150 mg/d aliskiren for 7 days (aliskiren group, <italic>n</italic> = 10) or did not receive aliskiren (control group, <italic>n</italic> = 6). Primary end points were systemic vascular resistance and cardiac index values. Repeated-measures analysis of variance (ANOVA) was used to assess variables before and after intervention. A two-sided <italic>p</italic>-value &lt; 0.05 was considered statistically significant.</p>
<p><italic>Results</italic>: Compared to pre-intervention levels, systemic vascular resistance was reduced by 20.4% in aliskiren patients, but it increased by 2.9% in control patients (<italic>p</italic> = 0.038). The cardiac index was not significantly increased by 19.0% in aliskiren patients, but decreased by 8.4% in control patients (<italic>p</italic> = 0.127). No differences in the pulmonary capillary or systolic blood pressure values were observed between the groups.</p>
<p><italic>Conclusion</italic>: Aliskiren use reduced systemic vascular resistance in patients with decompensated heart failure taking ACE inhibitors.</p>
</abstract>
<kwd-group>
<kwd>Congestive heart failure</kwd>
<kwd>renal insufficiency</kwd>
<kwd>renin</kwd>
<kwd>vascular resistance</kwd>
<kwd>vasodilation</kwd>
</kwd-group>
</article-meta>
</front>
<body>
<sec id="section1-1470320311423281" sec-type="intro">
<title>Introduction</title>
<p>Heart failure is a major cause of death and disability, with mortality rates reaching almost 20% per year. Understanding what factors impact heart failure-related mortality and morbidity may help in identifying patients who require more intense monitoring and therapy. Contemporary, evidence-based treatments include beta blockers, angiotensin-converting enzyme (ACE) inhibitors, aldosterone antagonists, and angiotensin receptor blockers (ARBs). Several trials related to heart failure therapies have shown the benefits of blocking the renin–angiotensin–aldosterone system (RAAS) at the ACE level (captopril),<sup><xref ref-type="bibr" rid="bibr1-1470320311423281">1</xref></sup> aldosterone level (aldosterone antagonist),<sup><xref ref-type="bibr" rid="bibr2-1470320311423281">2</xref>,<xref ref-type="bibr" rid="bibr3-1470320311423281">3</xref></sup> and angiotensin II type 1 (AT<sub>1</sub>) receptor level (candesartan).<sup><xref ref-type="bibr" rid="bibr4-1470320311423281">4</xref></sup>Reverse myocardial remodelling by RAAS blockade plays an important role in mortality reduction in heart failure. However, RAAS blockage with ACE inhibitors presents an escape phenomenon,<sup><xref ref-type="bibr" rid="bibr5-1470320311423281">5</xref></sup> with angiotensin II (Ang II) levels progressively increasing after their initial reduction.</p>
<p>Alternatively, renin inhibition induces a persistent Ang II reduction,<sup><xref ref-type="bibr" rid="bibr6-1470320311423281">6</xref></sup> which could be more advantageous for heart failure than ACE inhibitors. The renin inhibitor aliskiren has been studied in patients with hypertension<sup><xref ref-type="bibr" rid="bibr7-1470320311423281">7</xref></sup> and chronic kidney disease; however, few studies have assessed the use of aliskiren in heart failure patients.<sup><xref ref-type="bibr" rid="bibr8-1470320311423281">8</xref></sup> According to the results of the ALOFT<sup><xref ref-type="bibr" rid="bibr9-1470320311423281">9</xref></sup> study, aliskiren improves clinical symptoms and reduces B-type natriuretic peptide (BNP) levels in heart failure, without adverse effects such as hyperkalaemia, renal insufficiency, or worsening heart failure. Nevertheless, the haemodynamic effects of aliskiren have not been studied, nor has the drug been examined in the case of decompensated heart failure. The purpose of this study was to evaluate the haemodynamic effects of aliskiren in decompensated heart failure, in patients who were currently prescribed an ACE inhibitor.</p>
</sec>
<sec id="section2-1470320311423281" sec-type="materials|methods">
<title>Materials and methods</title>
<sec id="section3-1470320311423281">
<title>Patients</title>
<p>The setting of the study was the decompensated heart failure unit of the Cotoxo Hospital, Heart Institute (InCor), University of Sao Paulo. A total of 16 patients were enrolled. Inclusion criteria were hospitalisation due to decompensated heart failure, ACE inhibitor use, and an ejection fraction of &lt; 40%. Exclusion criteria were creatinine level &gt; 2.0 mg/dl, cardiac pacemaker, K<sup>+</sup> level &gt; 5.5 mEq/l, systolic blood pressure &lt; 70 mmHg, or current use of an aldosterone antagonist. The investigation conformed to the principles outlined in the Declaration of Helsinki (2004).</p>
</sec>
<sec id="section4-1470320311423281">
<title>Pulmonary artery catheterisation</title>
<p>According to current heart failure guidelines,<sup><xref ref-type="bibr" rid="bibr10-1470320311423281">10</xref></sup> pulmonary artery catheterisation is performed in patients when the signs and symptoms of heart failure do not resolve with initial therapy. Accordingly, the patients in the present study were submitted to pulmonary artery catheterisation. The cardiac index, pulmonary capillary wedge pressure, and systemic vascular resistance were measured using the Swan–Ganz technique<sup><xref ref-type="bibr" rid="bibr11-1470320311423281">11</xref></sup>. The haemodynamic condition was determined at baseline (before aliskiren treatment) and after 7 days of treatment with aliskiren (150 mg/d).</p>
</sec>
<sec id="section5-1470320311423281">
<title>Intervention</title>
<p>Patients were divided into two groups: 10 patients (aliskiren group) received aliskiren (150 mg/d) in the afternoon for 7 days, and six patients (the control group) did not receive aliskiren. All other patient drugs were maintained during the study. The aliskiren dose was reduced to 75 mg/d if the systolic blood pressure fell to &lt; 80 mmHg.</p>
</sec>
<sec id="section6-1470320311423281">
<title>End points</title>
<p>The primary end point was the systemic vascular resistance value after 7 days of aliskiren use. The secondary end point was the occurrence of adverse effects, such as hypotension (symptomatic systolic blood pressure of &lt; 80 mmHg), worsening renal function (serum creatinine &gt; 2.0 mg/dl), or hyperkalaemia (serum K<sup>+</sup> &gt; 5.5 mEq/l). Clinical worsening was defined as the patient requiring vasoactive drugs, as an increase in the intensity of dyspnoea, or as lowering the level of consciousness. Symptomatic hypotension was defined as systolic blood pressure &lt; 80 mmHg associated with symptoms of low cardiac output, such as dizziness and reduction of level of consciousness.</p>
</sec>
<sec id="section7-1470320311423281">
<title>Statistical analysis</title>
<p>Continuous variables were expressed as the mean ± standard deviation (SD). Repeated-measures analysis of variance (ANOVA) was used to compare variables before and after intervention between the aliskiren group and the control group. Categorical variables were expressed by the number and proportion, and were analysed by the Fisher’s exact test or chi-square test. A difference with a two-tailed <italic>p</italic>-value of &lt; 0.05 was considered statistically significant.</p>
</sec>
</sec>
<sec id="section8-1470320311423281" sec-type="results">
<title>Results</title>
<p>At total of 16 patients (14 men, two women, mean age: 60.3 years) were examined. The mean ejection fraction of the patients was 21.9 ± 6.7%. Baseline haemodynamic variables are shown in <xref ref-type="table" rid="table1-1470320311423281">Table 1</xref>.</p>
<table-wrap id="table1-1470320311423281" position="float">
<label>Table 1.</label>
<caption><p>Baseline characteristics</p></caption>
<graphic alternate-form-of="table1-1470320311423281" xlink:href="10.1177_1470320311423281-table1.tif"/>
<table>
<colgroup>
<col align="left"/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
</colgroup>
<thead>
<tr>
<th align="left">Characteristic</th>
<th align="left">Aliskiren (<italic>n</italic> = 10)</th>
<th align="left">Control (<italic>n</italic> = 6)</th>
<th align="left"><italic>P-value</italic></th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (SD), years</td>
<td>60.3 (11.6)</td>
<td>60.1 (4.9)</td>
<td>0.960</td>
</tr>
<tr>
<td>Ejection fraction (SD), mmHg</td>
<td>21.4 (6.2)</td>
<td>22.6 (8.0)</td>
<td>0.729</td>
</tr>
<tr>
<td>Weight (SD), kg</td>
<td>70.4 (17.8)</td>
<td>57.7 (6.8)</td>
<td>0.065</td>
</tr>
<tr>
<td>Hypertensive cardiomyopathy, <italic>n</italic> (%)</td>
<td>4 (40)</td>
<td>1 (16.7)</td>
<td>0.330</td>
</tr>
<tr>
<td>Systolic blood pressure (SD), mmHg</td>
<td>104.8 (17.4)</td>
<td>98.5 (10.9)</td>
<td>0.443</td>
</tr>
<tr>
<td>Cardiac index (SD), L/min/m<sup>2</sup></td>
<td>2.1 (0.7)</td>
<td>2.7 (1.0)</td>
<td>0.182</td>
</tr>
<tr>
<td>Pulmonary capillary pressure (SD), mmHg</td>
<td>28.8 (6.8)</td>
<td>39 (7.6)</td>
<td>0.015</td>
</tr>
<tr>
<td>Systemic vascular resistance (SD), dyn/s/m<sup>2</sup>/cm<sup>−5</sup></td>
<td>2.685 (673)</td>
<td>2.019 (802)</td>
<td>0.096</td>
</tr>
<tr>
<td>Creatinine (SD), mg/dl</td>
<td>1.34 (0.26)</td>
<td>1.18 (0.21)</td>
<td>0.192</td>
</tr>
<tr>
<td>Captopril (SD), mg/d</td>
<td>116.3 (44.9)</td>
<td>112.5 (41.1)</td>
<td>0.870</td>
</tr>
<tr>
<td>Carvedilol (%)</td>
<td>9 (90)</td>
<td>4 (67)</td>
<td>0.247</td>
</tr>
<tr>
<td>Furosemide (%)</td>
<td>9 (90)</td>
<td>5 (83)</td>
<td>0.696</td>
</tr>
<tr>
<td>New York Heart Association functional class IV heart failure (%)</td>
<td>10 (100)</td>
<td>6 (100)</td>
<td>0.999</td>
</tr>
</tbody>
</table>
</table-wrap>
<p>Compared to baseline (pre-intervention) levels, the average post-intervention systemic vascular resistance was reduced by 20.4% in the aliskiren group (from 2685.3 ± 673.3 to 2137.9 ± 684.9 dyn/s/m<sup>2</sup>/cm<sup>−5</sup>) and increased by 2.9% in the control group (<italic>p</italic> = 0.038) (<xref ref-type="fig" rid="fig1-1470320311423281">Figure 1</xref>). In the aliskiren group, the cardiac index improved by 19.0%, from 2.12 ± 0.70 to 2.52 ± 0.68 (<italic>p</italic> = 0.159). The pulmonary capillary pressure decreased by 28.5% (from 28.8 to 20.6 mmHg) in the aliskiren group, compared to a 20% decrease in the control group (<italic>p</italic> = 0.257). The systolic blood pressure decreased from 104.8 ± 17.4 to 92.6 ± 14.5 mmHg in the aliskiren group and from 98.5 ± 10.9 to 96.3 ±12.5 mmHg in the control group (<italic>p</italic> = 0.331). In the aliskiren group the heart rate decreased from 81.0 (SD = 14.7) to 74.5 (SD = 10.4), and in the control group from 90.2 (SD = 19.5) to 78.2 bpm (SD = 10.4), without statistical difference between the groups (<italic>p</italic> = 0.553).</p>
<fig id="fig1-1470320311423281" position="float">
<label>Figure 1.</label>
<caption><p>Post-intervention systemic vascular resistance response in the aliskiren and control groups compared to baseline (pre-intervention) levels. SEM: standard error of the mean.</p></caption>
<graphic xlink:href="10.1177_1470320311423281-fig1.tif"/>
</fig>
<p>Patients in the aliskiren group did not display adverse effects, such as hyperkalaemia (from 4.68 ± 0.43 to 4.70 ± 0.78 mEq/l; <italic>p</italic> = 0.932), worsening kidney function (<italic>p</italic> = 0.954), or symptomatic hypotension (<italic>p</italic> = 0.331). Clinical improvement or improved symptoms and signs occurred in six of the 10 patients in the aliskiren group.</p>
</sec>
<sec id="section9-1470320311423281" sec-type="discussion">
<title>Discussion</title>
<p>The main finding of the present study is that aliskiren combined with ACE inhibitor use reduced systemic vascular resistance levels in patients hospitalised for decompensated severe heart failure.</p>
<p>The RAAS is activated in systolic heart failure. Elevation of renin, Ang II, and aldosterone levels occurs alongside adrenergic activation and increased BNP and vasopressin levels. Current heart failure therapies include beta blockers, aldosterone antagonists, ACE inhibitors, and AT<sub>1</sub> receptor blockers. The combination of these drugs provides additional benefits. The benefits of adding a renin inhibition therapy (such as aliskiren) to a conventional heart failure treatment have not been studied.</p>
<p>The RAAS has dual ACE and non-ACE pathways of Ang II production. Cathepsin and chymase convert angiotensin I (Ang I) to Ang II, with only 11% of Ang II being produced by ACE.<sup><xref ref-type="bibr" rid="bibr12-1470320311423281">12</xref></sup> Furthermore, peptides other than Ang I and Ang II have been described, as well as Ang II receptors other than AT<sub>1</sub>.<sup><xref ref-type="bibr" rid="bibr13-1470320311423281">13</xref></sup> Therefore, complete blockade of the RAAS is very unlikely. Blockade of the RAAS by inhibiting renin could be more effective than blockade with ACE inhibitors or ARBs, which block the system at the first steps. Renin has specificity for a unique substrate, angiotensinogen.<sup><xref ref-type="bibr" rid="bibr14-1470320311423281">14</xref></sup> In addition to the escape phenomenon displayed by ACE inhibitors, ARBs similarly induce increased Ang II levels by negative feedback, leading to AT<sub>2</sub> stimulation. Moreover, when heart failure is treated with ARBs but without ACE inhibitors, bradykinin levels are decreased and a reduced vasodilator effect is observed.</p>
<p>In normotensive individuals, aliskiren reduces plasmatic renin activity; consequently, there is a reduction of plasmatic Ang II and aldosterone levels.<sup><xref ref-type="bibr" rid="bibr15-1470320311423281">15</xref></sup> The first study with aliskiren in heart failure, the Aliskiren Observation of Heart Failure Treatment (ALOFT) study, examined the neurohormonal effects of the drug. The ALOFT study included patients with heart failure and plasma BNP levels &gt; 100 pg/ml, who had been treated with either an ACE inhibitor or ARB. The patients received placebo (<italic>n</italic> = 146) or aliskiren 150 mg/d (<italic>n</italic> = 156) for 3 months. Renin activity decreased with aliskiren, leading to increased plasmatic renin concentrations by negative feedback and reduced urinary aldosterone excretion. These findings demonstrated a persistent blockade of the final step of the RAAS for 12 weeks, without an escape phenomenon. Nevertheless, 62% of the ALOFT patients were in the New York Heart Association (NYHA) class II, compared to the present study where patients presented more advanced heart failure (all in class IV of the NYHA). The recent Aliskiren Study in Post-MI Patients to Reduce Remodeling (ASPIRE) study revealed that aliskiren did not improve ventricular systolic volume in 820 post-infarct patients within 36 weeks of follow-up. However, aliskiren also did not increase the occurrence of severe adverse effects.<sup><xref ref-type="bibr" rid="bibr16-1470320311423281">16</xref></sup></p>
<sec id="section10-1470320311423281">
<title>Vasodilation in decompensated heart failure</title>
<p>Changes in the RAAS happen during a decompensation of heart failure. For example, additional activation is demonstrated by the increase in plasmatic renin activity and aldosterone levels.<sup><xref ref-type="bibr" rid="bibr17-1470320311423281">17</xref></sup> Consequently, increases in systemic vascular resistance and decreases in cardiac index can worsen symptoms. Previous studies have demonstrated that the addition of vasodilators enhances haemodynamic and clinical conditions. Add-on therapy with isosorbide-hydralazine reduces systemic vascular resistance and increases the cardiac index, thereby reducing mortality.<sup><xref ref-type="bibr" rid="bibr18-1470320311423281">18</xref></sup> Candesartan as an add-on therapy improves the neurohormonal condition, reducing BNP levels and improving the overall quality of life.<sup><xref ref-type="bibr" rid="bibr19-1470320311423281">19</xref></sup></p>
<p>The key finding of our study is that aliskiren provided favourable haemodynamic improvement in decompensated heart failure. Before intervention, the patients did not compensate with an ACE inhibitor alone, had severely depressed ejection fractions, and heart failure symptoms at rest, all of which are poor prognostic indicators. It has been demonstrated that aliskiren reduces neurohormonal activation; however, the haemodynamic response of this aliskiren action has not been proved. Although reduced morbidity/mortality is the main target in heart failure treatment, some authors defend a surrogate end point (haemodynamic improvement) as a therapeutic goal in decompensation.<sup><xref ref-type="bibr" rid="bibr20-1470320311423281">20</xref></sup> Unlike stable chronic heart failure, during decompensation symptom improvement occurs through haemodynamic improvement.<sup><xref ref-type="bibr" rid="bibr21-1470320311423281">21</xref></sup> Therefore, an add-on therapy with aliskiren could be considered worthwhile.</p>
<p>The ALOFT study reported no significant change in the reported adverse effects with aliskiren treatment (worsening renal function: placebo 2.1% vs. aliskiren 0%; hyperkalaemia: placebo 8.3% vs. aliskiren 8.3%),<sup><xref ref-type="bibr" rid="bibr9-1470320311423281">9</xref></sup> although it did not assess decompensated heart failure. We likewise observed no differences in adverse events in the present study.</p>
</sec>
<sec id="section11-1470320311423281">
<title>Study limitations</title>
<p>The use of aliskiren in decompensated heart failure constitutes an off-label use. This was an open-design study without the use of a placebo in the control group and without randomisation. We evaluated the short-term effects of aliskiren, but we did not assess its long-term safety and clinical outcomes, such as mortality.</p>
<p>In summary, in our study, aliskiren reduced systemic vascular resistance in patients with decompensated heart failure. Randomised, placebo-controlled studies should be carried out to assess the clinical importance of these findings.</p>
</sec>
</sec>
</body>
<back>
<fn-group>
<fn fn-type="financial-disclosure">
<p>This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors.</p>
</fn>
<fn fn-type="conflict">
<p>None declared.</p>
</fn>
</fn-group>
<ref-list>
<title>References</title>
<ref id="bibr1-1470320311423281">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Pfeffer</surname><given-names>MA</given-names></name>
<name><surname>Braunwald</surname><given-names>E</given-names></name>
<name><surname>Moyé</surname><given-names>LA</given-names></name>
<name><surname>Basta</surname><given-names>L</given-names></name>
<name><surname>Brown</surname><given-names>EJ</given-names><suffix>Jr</suffix></name>
<name><surname>Cuddy</surname><given-names>TE</given-names></name>
<etal/>
</person-group>. <article-title>Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators</article-title>. <source>N Engl J Med</source> <year>1992</year>; <volume>327</volume>: <fpage>669</fpage>–<lpage>677</lpage>.</citation>
</ref>
<ref id="bibr2-1470320311423281">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Pitt</surname><given-names>B</given-names></name>
<name><surname>Zannad</surname><given-names>F</given-names></name>
<name><surname>Remme</surname><given-names>WJ</given-names></name>
<name><surname>Cody</surname><given-names>R</given-names></name>
<name><surname>Castaigne</surname><given-names>A</given-names></name>
<name><surname>Perez</surname><given-names>A</given-names></name>
<etal/>
</person-group>. <article-title>The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators</article-title>. <source>N Engl J Med</source> <year>1999</year>; <volume>341</volume>: <fpage>709</fpage>–<lpage>717</lpage>.</citation>
</ref>
<ref id="bibr3-1470320311423281">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Zannad</surname><given-names>F</given-names></name>
<name><surname>McMurray</surname><given-names>JJ</given-names></name>
<name><surname>Krum</surname><given-names>H</given-names></name>
<name><surname>van Veldhuisen</surname><given-names>DJ</given-names></name>
<name><surname>Swedberg</surname><given-names>K</given-names></name>
<name><surname>Shi</surname><given-names>H</given-names></name>
<etal/>
</person-group>. <article-title>Eplerenone in patients with systolic heart failure and mild symptoms</article-title>. <source>N Engl J Med</source> <year>2011</year>; <volume>364</volume>: <fpage>11</fpage>–<lpage>21</lpage>.</citation>
</ref>
<ref id="bibr4-1470320311423281">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>McMurray</surname><given-names>JJ</given-names></name>
<name><surname>Ostergren</surname><given-names>J</given-names></name>
<name><surname>Swedberg</surname><given-names>K</given-names></name>
<name><surname>Granger</surname><given-names>CB</given-names></name>
<name><surname>Held</surname><given-names>P</given-names></name>
<name><surname>Michelson</surname><given-names>EL</given-names></name>
<etal/>
</person-group>. <article-title>Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial</article-title>. <source>Lancet</source> <year>2003</year>; <volume>362</volume>: <fpage>767</fpage>–<lpage>771</lpage>.</citation>
</ref>
<ref id="bibr5-1470320311423281">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Juillerat</surname><given-names>L</given-names></name>
<name><surname>Nussberger</surname><given-names>J</given-names></name>
<name><surname>Ménard</surname><given-names>J</given-names></name>
<name><surname>Mooser</surname><given-names>V</given-names></name>
<name><surname>Christen</surname><given-names>Y</given-names></name>
<name><surname>Waeber</surname><given-names>B</given-names></name>
<etal/>
</person-group>. <article-title>Determinants of angiotensin II generation during converting enzyme inhibition</article-title>. <source>Hypertension</source> <year>1990</year>; <volume>16</volume>: <fpage>564</fpage>–<lpage>572</lpage>.</citation>
</ref>
<ref id="bibr6-1470320311423281">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Seed</surname><given-names>A</given-names></name>
<name><surname>Gardner</surname><given-names>R</given-names></name>
<name><surname>McMurray</surname><given-names>J</given-names></name>
<name><surname>Hillier</surname><given-names>C</given-names></name>
<name><surname>Murdoch</surname><given-names>D</given-names></name>
<name><surname>MacFadyen</surname><given-names>R</given-names></name>
<etal/>
</person-group>. <article-title>Neurohumoral effects of the new orally active renin inhibitor, aliskiren, in chronic heart failure</article-title>. <source>Eur J Heart Fail</source> <year>2007</year>; <volume>9</volume>: <fpage>1120</fpage>–<lpage>1127</lpage>.</citation>
</ref>
<ref id="bibr7-1470320311423281">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Zheng</surname><given-names>Z</given-names></name>
<name><surname>Shi</surname><given-names>H</given-names></name>
<name><surname>Jia</surname><given-names>J</given-names></name>
<name><surname>Li</surname><given-names>D</given-names></name>
<name><surname>Lin</surname><given-names>S</given-names></name>
</person-group>. <article-title>A systematic review and meta-analysis of aliskiren and angiotension receptor blockers in the management of essential hypertension</article-title>. <source>J Renin Angiotensin Aldosterone Syst</source> <year>2011</year>; <volume>12</volume>: <fpage>102</fpage>–<lpage>112</lpage>.</citation>
</ref>
<ref id="bibr8-1470320311423281">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Sever</surname><given-names>PS</given-names></name>
<name><surname>Gradman</surname><given-names>PH</given-names></name>
<name><surname>Azizi</surname><given-names>M</given-names></name>
</person-group>. <article-title>Managing cardiovascular and renal risk: the potential of direct renin inhibition</article-title>. <source>J Renin Angiotensin Aldosterone Syst</source> <year>2009</year>; <volume>10</volume>: <fpage>65</fpage>–<lpage>76</lpage>.</citation>
</ref>
<ref id="bibr9-1470320311423281">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>McMurray</surname><given-names>JJ</given-names></name>
<name><surname>Pitt</surname><given-names>B</given-names></name>
<name><surname>Latini</surname><given-names>R</given-names></name>
<name><surname>Maggioni</surname><given-names>AP</given-names></name>
<name><surname>Solomon</surname><given-names>SD</given-names></name>
<name><surname>Keefe</surname><given-names>DL</given-names></name>
<etal/>
</person-group>. <article-title>Effects of the oral direct renin inhibitor aliskiren in patients with symptomatic heart failure</article-title>. <source>Circ Heart Fail</source> <year>2008</year>; <volume>1</volume>: <fpage>17</fpage>–<lpage>24</lpage>.</citation>
</ref>
<ref id="bibr10-1470320311423281">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Hunt</surname><given-names>SA</given-names></name>
<name><surname>Abraham</surname><given-names>WT</given-names></name>
<name><surname>Chin</surname><given-names>MH</given-names></name>
<name><surname>Feldman</surname><given-names>AM</given-names></name>
<name><surname>Francis</surname><given-names>GS</given-names></name>
<name><surname>Ganiats</surname><given-names>TG</given-names></name>
<etal/>
</person-group>. <article-title>2009 Focused update incorporated into the ACC/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults. A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines Developed in Collaboration With the International Society for Heart and Lung Transplantation</article-title>. <source>J Am Coll Cardiol</source> <year>2009</year>; <volume>53</volume>: <fpage>e1</fpage>–<lpage>e90</lpage>.</citation>
</ref>
<ref id="bibr11-1470320311423281">
<citation citation-type="book">
<person-group person-group-type="author">
<name><surname>Voyce</surname><given-names>SJ</given-names></name>
<name><surname>Urbach</surname><given-names>D</given-names></name>
<name><surname>Rippe</surname><given-names>JM</given-names></name>
</person-group>. <article-title>Pulmonary artery catheters</article-title>. In: <person-group person-group-type="editor">
<name><surname>Rippe</surname><given-names>JM</given-names></name>
<name><surname>Irwin</surname><given-names>RS</given-names></name>
<name><surname>Alpert</surname><given-names>JS</given-names></name>
<name><surname>Fink</surname><given-names>MP</given-names></name>
</person-group> (eds.). <source>Intensive Care Medicine</source>, <edition>2nd ed.</edition> <publisher-loc>Boston</publisher-loc>: <publisher-name>Little, Brown and Company</publisher-name>, <year>1991</year>, pp. <fpage>48</fpage>–<lpage>72</lpage>.</citation>
</ref>
<ref id="bibr12-1470320311423281">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Urata</surname><given-names>H</given-names></name>
<name><surname>Healy</surname><given-names>B</given-names></name>
<name><surname>Stewart</surname><given-names>RW</given-names></name>
<name><surname>Bumpus</surname><given-names>FM</given-names></name>
<name><surname>Husain</surname><given-names>A</given-names></name>
</person-group>. <article-title>Angiotensin II-forming pathways in normal and failing human hearts</article-title>. <source>Circ Res</source> <year>1990</year>; <volume>66</volume>: <fpage>883</fpage>–<lpage>890</lpage>.</citation>
</ref>
<ref id="bibr13-1470320311423281">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Iusuf</surname><given-names>D</given-names></name>
<name><surname>Henning</surname><given-names>RH</given-names></name>
<name><surname>van Gilst</surname><given-names>WH</given-names></name>
<name><surname>Roks</surname><given-names>AJ</given-names></name>
</person-group>. <article-title>Angiotensin-(1–7): pharmacological properties and pharmacotherapeutic perspectives</article-title>. <source>Eur J Pharmacol</source> <year>2008</year>; <volume>585</volume>: <fpage>303</fpage>–<lpage>312</lpage>.</citation>
</ref>
<ref id="bibr14-1470320311423281">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Skeggs</surname><given-names>LT</given-names><suffix>Jr</suffix></name>
<name><surname>Kahn</surname><given-names>JR</given-names></name>
<name><surname>Lentz</surname><given-names>K</given-names></name>
<name><surname>Shumway</surname><given-names>NP</given-names></name>
</person-group>. <article-title>The preparation, purification, and amino acid sequence of a polypeptide renin substrate</article-title>. <source>J Exp Med</source> <year>1957</year>; <volume>106</volume>: <fpage>439</fpage>–<lpage>453</lpage>.</citation>
</ref>
<ref id="bibr15-1470320311423281">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Azizi</surname><given-names>M</given-names></name>
<name><surname>Ménard</surname><given-names>J</given-names></name>
<name><surname>Bissery</surname><given-names>A</given-names></name>
<name><surname>Guyene</surname><given-names>TT</given-names></name>
<name><surname>Bura-Rivière</surname><given-names>A</given-names></name>
</person-group>. <article-title>Hormonal and hemodynamic effects of aliskiren and valsartan and their combination in sodium-replete normotensive individuals</article-title>. <source>Clin J Am Soc Nephrol</source> <year>2007</year>; <volume>2</volume>: <fpage>947</fpage>–<lpage>955</lpage>.</citation>
</ref>
<ref id="bibr16-1470320311423281">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Solomon</surname><given-names>SD</given-names></name>
<name><surname>Shin</surname><given-names>SH</given-names></name>
<name><surname>Shah</surname><given-names>A</given-names></name>
<name><surname>Skali</surname><given-names>H</given-names></name>
<name><surname>Desai</surname><given-names>A</given-names></name>
<name><surname>Kober</surname><given-names>L</given-names></name>
<etal/>
</person-group>. <article-title>Effect of the direct renin inhibitor aliskiren on left ventricular remodelling following myocardial infarction with systolic dysfunction</article-title>. <source>Eur Heart J</source> <year>2011</year>; <volume>32</volume>: <fpage>1227</fpage>–<lpage>1234</lpage>.</citation>
</ref>
<ref id="bibr17-1470320311423281">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Johnson</surname><given-names>W</given-names></name>
<name><surname>Omland</surname><given-names>T</given-names></name>
<name><surname>Hall</surname><given-names>C</given-names></name>
<name><surname>Lucas</surname><given-names>C</given-names></name>
<name><surname>Myking</surname><given-names>OL</given-names></name>
<name><surname>Collins</surname><given-names>C</given-names></name>
<etal/>
</person-group>. <article-title>Neurohormonal activation rapidly decreases after intravenous therapy with diuretics and vasodilators for class IV heart failure</article-title>. <source>J Am Coll Cardiol</source> <year>2002</year>; <volume>39</volume>: <fpage>1623</fpage>–<lpage>1629</lpage>.</citation>
</ref>
<ref id="bibr18-1470320311423281">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Mullens</surname><given-names>W</given-names></name>
<name><surname>Abrahams</surname><given-names>Z</given-names></name>
<name><surname>Francis</surname><given-names>GS</given-names></name>
<name><surname>Sokos</surname><given-names>G</given-names></name>
<name><surname>Starling</surname><given-names>RC</given-names></name>
<name><surname>Young</surname><given-names>JB</given-names></name>
<etal/>
</person-group>. <article-title>Usefulness of Isosorbide Dinitrate and Hydralazine as add-on therapy in patients discharged for advanced decompensated heart failure</article-title>. <source>Am J Cardiol</source> <year>2009</year>; <volume>103</volume>: <fpage>1113</fpage>–<lpage>1119</lpage>.</citation>
</ref>
<ref id="bibr19-1470320311423281">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Mitrovic</surname><given-names>V</given-names></name>
<name><surname>Appel</surname><given-names>KF</given-names></name>
<name><surname>Proskynitopoulos</surname><given-names>N</given-names></name>
<name><surname>Dereli</surname><given-names>S</given-names></name>
<name><surname>Hamm</surname><given-names>CW</given-names></name>
</person-group>. <article-title>Effects of candesartan cilexetil ‘‘add-on’’ treatment in congestive heart failure outpatients in daily practice</article-title>. <source>Clin Res Cardiol</source> <year>2009</year>; <volume>98</volume>: <fpage>379</fpage>–<lpage>389</lpage>.</citation>
</ref>
<ref id="bibr20-1470320311423281">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Gheorghiade</surname><given-names>M</given-names></name>
<name><surname>De Luca</surname><given-names>L</given-names></name>
<name><surname>Fonarow</surname><given-names>GC</given-names></name>
<name><surname>Filippatos</surname><given-names>G</given-names></name>
<name><surname>Metra</surname><given-names>M</given-names></name>
<name><surname>Francis</surname><given-names>GS</given-names></name>
</person-group>. <article-title>Pathophysiologic targets in the early phase of acute heart failure syndromes</article-title>. <source>Am J Cardiol</source> <year>2005</year>; <volume>96</volume>: <fpage>11G</fpage>–<lpage>17G</lpage>.</citation>
</ref>
<ref id="bibr21-1470320311423281">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Binanay</surname><given-names>C</given-names></name>
<name><surname>Califf</surname><given-names>RM</given-names></name>
<name><surname>Hasselblad</surname><given-names>V</given-names></name>
<name><surname>O’Connor</surname><given-names>CM</given-names></name>
<name><surname>Shah</surname><given-names>MR</given-names></name>
<name><surname>Sopko</surname><given-names>G</given-names></name>
<etal/>
</person-group>. <article-title>Evaluation study of congestive heart failure and pulmonary artery catheterization effectiveness: the ESCAPE trial</article-title>. <source>JAMA</source> <year>2005</year>; <volume>294</volume>: <fpage>1625</fpage>–<lpage>1633</lpage>.</citation>
</ref>
</ref-list>
</back>
</article>